OCULIS

oculis-logo

The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME (diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. Furthermore, the technique has been demonstrated to allow diseases at the anterior part of the eye to be treated with a reduced number of topical applications compared to conventional eye-drops.

#SimilarOrganizations #People #Financial #Event #Website #More

OCULIS

Social Links:

Industry:
Biotechnology Health Care Pharmaceutical

Founded:
2003-01-01

Address:
Reykjavík, Gullbringusysla, Iceland

Country:
Iceland

Website Url:
http://www.oculis.com

Total Employee:
11+

Status:
Active

Contact:
+354 546-4440

Email Addresses:
[email protected]

Total Funding:
94.36 M USD

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Apple Mobile Web Clips Icon WordPress Font Awesome Apache


Similar Organizations

aimmune-therapeutics-logo

Aimmune Therapeutics

Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.

immutep-logo

Immutep

Immutep is a biopharmaceutical company developing immunotherapeutics in oncology.

salix-pharmaceuticals-logo

Salix Pharmaceuticals

Salix Pharmaceuticals is a specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders.


Current Advisors List

anthony-rosenberg_image

Anthony Rosenberg Board Member @ Oculis
Board_member

bart-dzikowski_image

Bart Dzikowski Board Member @ Oculis
Board_member
2019-05-01

lionel-carnot_image

Lionel Carnot Board Member @ Oculis
Board_member
2017-12-01

arni-blöndal_image

Arni Blöndal Board Member @ Oculis
Board_member
2016-08-01

not_available_image

Sylvia He Board of Directors @ Oculis
Board_member
2021-05-04

riad-sherif_image

Riad Sherif Board Member @ Oculis
Board_member

rob-hopfner_image

Rob Hopfner Board Member @ Oculis
Board_member

not_available_image

Vanessa Huang Board of Directors @ Oculis
Board_member
2021-05-04

Current Employees Featured

einar-stefansson_image

Einar Stefansson
Einar Stefansson Chief Medical Officer & Co-Founder @ Oculis
Chief Medical Officer & Co-Founder
2004-02-01

not_available_image

Páll Ragnar Jóhannesson
Páll Ragnar Jóhannesson Chief Executive Officer @ Oculis
Chief Executive Officer

riad-sherif_image

Riad SHERIF
Riad SHERIF CEO @ Oculis
CEO
2017-11-01

sylvia-cheung_image

Sylvia Cheung
Sylvia Cheung Chief Financial Officer @ Oculis
Chief Financial Officer
2020-09-01

thorsteinn-loftsson_image

Thorsteinn Loftsson
Thorsteinn Loftsson Chief Scientific Officer @ Oculis
Chief Scientific Officer

marcia-de-souza-lima_image

Marcia de Souza Lima
Marcia de Souza Lima Chief Medical Officer @ Oculis
Chief Medical Officer
2020-02-01

gudrun-marta-asgrimsdottir_image

Gudrun Marta Asgrimsdottir
Gudrun Marta Asgrimsdottir VP, Pharmaceutical Development @ Oculis
VP, Pharmaceutical Development
2010-08-01

not_available_image

Bastian Dehmel
Bastian Dehmel Chief Development Officer @ Oculis
Chief Development Officer
2022-01-01

david-p-bingaman_image

David P. Bingaman
David P. Bingaman Vice President , Head & Global Clinical Development @ Oculis
Vice President , Head & Global Clinical Development
2020-06-01

frédéric-pilotaz_image

Frédéric Pilotaz
Frédéric Pilotaz VP, Technology & Pharmaceutical Sciences @ Oculis
VP, Technology & Pharmaceutical Sciences
2020-03-01

Founder


einar-stefansson_image

Einar Stefansson

thorsteinn-loftsson_image

Thorsteinn Loftsson

Investors List

hyfinity-investments_image

Hyfinity Investments

Hyfinity Investments investment in Series C - Oculis

bay-city-capital_image

Bay City Capital

Bay City Capital investment in Series C - Oculis

nan-fung-life-sciences_image

Nan Fung Life Sciences

Nan Fung Life Sciences investment in Series C - Oculis

bioveda-china-fund_image

BVCF

BVCF investment in Series C - Oculis

tekla-capital-management_image

Tekla Capital Management

Tekla Capital Management investment in Series C - Oculis

silfurberg_image

Silfurberg

Silfurberg investment in Series C - Oculis

venture-capital-fund-brunnur_image

Brunnur Ventures

Brunnur Ventures investment in Series C - Oculis

pivotal-bioventure-partners_image

Pivotal bioVenture Partners

Pivotal bioVenture Partners investment in Series C - Oculis

vi-partners_image

VI Partners

VI Partners investment in Series C - Oculis

novartis-venture-fund_image

Novartis Venture Fund

Novartis Venture Fund investment in Series C - Oculis

Official Site Inspections

http://www.oculis.com Semrush global rank: 3.27 M Semrush visits lastest month: 5.03 K

  • Host name: 141.193.213.10
  • IP address: 141.193.213.10
  • Location: United States
  • Latitude: 37.751
  • Longitude: -97.822
  • Timezone: America/Chicago

Loading ...

More informations about "Oculis"

Oculis | Investors and Media

Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) purposefully driven to save sight and improve eye care. Oculis’ highly differentiated pipeline comprises multiple …See details»

About Us - Ophthalmology Companies - Oculis

Oculis is a global biopharmaceutical company purposefully driven to save sight and improve eye care. We are driven by patients suffering from eye diseases to develop transformative innovations that have the potential to address …See details»

Meet Our Team - Oculis

We are a global biopharmaceutical company purposefully driven to save sight and improve eye care. Led by an experienced management team and supported by leading investors and …See details»

Oculis - Crunchbase Company Profile & Funding

The Oculis drug delivery platform allows diseases such as DME (diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive …See details»

Oculis | Corporate Governance

The Board of Directors of Oculis Holding AG (the “Company”) sets high standards for our employees, officers and directors. Implicit in this philosophy is the importance of sound …See details»

Oculis Holding - Overview, News & Similar companies - ZoomInfo

Aug 12, 2024 Who is Oculis Holding. Headquartered in Zug, Switzerland with global operations in Europe, the U.S. and China. Oculis is a biopharmaceutical company focused on developing …See details»

Oculis | European Clinical Trials Information Network

Oculis is a Swiss-based biopharmaceutical company that specializes in developing innovative treatments for ocular diseases. Founded in 2003, the company has a rich history of pioneering …See details»

Oculis Holding Company Profile 2024: Stock …

Oculis Holding General Information Description. Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular …See details»

Oculis Operations Sàrl – Swiss Biotech

Oculis is a biopharmaceutical company purposefully driven to save sight & improve eye care. Oculis’ highly differentiated pipeline comprises multiple innovative product candidates in …See details»

Oculis Company Profile - Office Locations, Competitors, Revenue …

Oculis is a biopharmaceutical company focused on eye care. Its products include OCS-01, a topical retinal candidate for diabetic macular edema, OCS-02, a topical biologic candidate for …See details»

Oculis - Org Chart, Teams, Culture & Jobs - The Org

Oculis is a clinical stage biopharmaceutical company whose mission is to develop novel topical treatments (eye drops) for ophthalmic diseases for both back-and front-of-the-eye in order to …See details»

FAQs - Oculis

Continental Stock Transfer & Trust Company 1 State Street, 30th Floor New York, New York 10004. For help with change of address, transfer of shares, loss of share certificates, …See details»

Oculis Reports Q3 2024 Financial Results and Provides Company …

Nov 7, 2024 Merger and listing expense, which was a one-time non-cash expense CHF 34.9 million or $38.2 million in total operating expenses in the nine months ended September 30, …See details»

Our Culture: Mission To Save Sight & Improve Eye Care- Oculis

At Oculis, we believe that a thriving culture is an essential component of our success. We are committed to creating and fostering a positive environment where our employees can bring …See details»

Oculis | Oculis Announces Completion of Enrollment in Phase 2 ...

ZUG, Switzerland, May 08, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully …See details»

Oculis: Vision for a Paradigm Shift in Ophthalmology Delivery

Aug 11, 2021 Oculis’ second asset, OCS-02, is currently in Phase II. This is a first-in-class anti-TNFα antibody in-licenced from Novartis, and based on a proprietary single-chain antibody …See details»

Oculis | CAREERS

Oculis is a clinical stage biopharmaceutical company whose mission is to develop novel topical treatments (eye drops) for ophthalmic diseases for both back- and front-of-the-eye in order to …See details»

Rethinking Ophthalmology - Oculis

Aug 8, 2023 Oculis announces positive top line results from DIAMOND Stage 1 phase 3 trial in diabetic macular edema with OCS-01 eye drops. .May 22, 2023. 3. Shulman S, et al. Acta …See details»

Ophthalmic Eye Drops For Dry Eyes Treatment - Oculis

Explore Oculis Ophthalmic Eye Drops For Dry Eyes Treatment. Skip to content. Contact Us; Join Us; Linkedin; Submit Search. Our Company. About Us; Governance; Our Culture; Our …See details»

linkstock.net © 2022. All rights reserved